[177Lu]Lu-DOTAGA.FAPi二聚体治疗放射性碘难治性滤泡细胞来源甲状腺癌的长期结局
这项回顾性研究纳入73例多线治疗后的放射性碘难治性滤泡细胞来源甲状腺癌患者,65例接受[177Lu]Lu-DOTAGA.FAPi二聚体单药治疗,8例接受[177Lu]Lu/[225Ac]Ac串联治疗;中位无进展生存期29个月,中位总生存期32个月,3级贫血4例(5.4%)、3级血小板减少3例(4%),未见3级肾或肝毒性。
要点
- 中位无进展生存期29个月(CI 14-34个月),中位总生存期32个月(CI 21-40个月)。
- 4例(5.4%)出现3级贫血,3例(4%)出现3级血小板减少,未见3级肾或肝毒性。
- 作者认为该疗法在侵袭性放射性碘难治性甲状腺癌中显示出有前景的安全性和疗效。
核心结论
- [177Lu]Lu-DOTAGA.FAPi二聚体治疗在侵袭性放射性碘难治性甲状腺癌中显示出有前景的安全性和疗效,中位无进展生存期和中位总生存期分别为29个月和32个月,不良事件可控。
- 作者指出需要前瞻性临床试验将[177Lu]Lu-DOTAGA.FAPi二聚体治疗与其他治疗进行比较,以确认本研究结果。
研究设计与样本
- 回顾性研究,纳入73例既往接受过多线治疗的放射性碘难治性滤泡细胞来源甲状腺癌患者。
- 73例患者中,65例接受[177Lu]Lu-DOTAGA.FAPi二聚体单药治疗,每周期中位活度5.5 GBq,间隔8周;其余8例接受[177Lu]Lu/[225Ac]Ac-DOTAGA.FAPi二聚体串联治疗,中位2周期[177Lu]Lu-DOTAGA.FAPi二聚体后接1周期[225Ac]Ac-DOTAGA.FAPi二聚体,间隔8周。
- 患者接受[177Lu]Lu-DOTAGA.FAPi二聚体中位累积活度22.2 GBq(范围4 GBq-55.5 GBq),共1至9周期,中位3周期。
- 主要终点为无进展生存期和总生存期;次要终点包括PERCIST标准疗效评估和依据不良事件通用术语标准(V5.0)的安全性评估。
主要发现
- 共纳入37例女性和36例男性患者,平均年龄54.3岁(范围27-80岁)。
- 73例患者中20例死亡,其中16例死于甲状腺癌;19例出现疾病进展。
- 估计中位无进展生存期为29个月(CI 14-34个月),估计中位总生存期为32个月(CI 21-40个月)。
- 4例(5.4%)出现3级贫血,其中3例主要与骨转移相关,1例与颈部肿瘤肿块出血相关;3例(4%)出现3级血小板减少;未见3级肾毒性或肝毒性。
局限性
- 作者指出需要前瞻性临床试验将[177Lu]Lu-DOTAGA.FAPi二聚体治疗与其他治疗进行比较,以确认本研究结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Aim: The study aimed to analyze the long-term outcomes of [177Lu]Lu-DOTAGA.FAPi dimer therapy in individuals diagnosed with radioiodine-resistant (RAI-R) follicular cell-derived thyroid cancer. Materials and Methods: In this retrospective study, 73 patients with RAI-R follicular thyroid carcinoma who had undergone multiple lines of previous treatments were included. Following [68Ga]Ga-DOTA.SA.FAPi positron emission tomography-computed tomography scan, among the 73 patients, 65 received [177Lu]Lu-DOTAGA.FAPi dimer monotherapy with a median activity of 5.5 GBq per cycle at 8-week intervals. The remaining eight patients underwent tandem [177Lu]Lu/[225Ac]Ac-DOTAGA.FAPi dimer therapy, consisting of a median of two cycles of [177Lu]Lu-DOTAGA.FAPi dimer followed by one cycle of [225Ac]Ac-DOTAGA.FAPi dimer, also at 8-week intervals. The primary endpoint included progression-free survival (PFS) and overall survival (OS). Secondary endpoints included PERCIST criteria response assessment and safety assessment according to Common Terminology Criteria for Adverse Events (V5.0). Results: We enrolled 37 female and 36 male patients, with a mean age of 54.3 years (range: 27 - 80 years). The patients received a median cumulative activity of 22.2 GBq (range, 4 GBq-55.5 GBq) of [177Lu]Lu-DOTAGA-FAPi dimer over one to nine cycles, with a median of three cycles. Among 73 patients, 20 died and 16 deaths were due to thyroid cancer. Nineteen patients experienced disease progression, with an estimated median PFS of 29 months [CI 14-34 months]. The estimated median OS was 32 months [CI 21-40 months]. Four patients (5.4%) encountered grade III anemia, primarily linked to bone metastasis in three cases and neck tumor mass bleed in one. Grade III thrombocytopenia occurred in three patients (4%). No grade III renal or hepatotoxicity was observed. Conclusion: In this study, [177Lu]Lu-DOTAGA.FAPi dimer therapy showed promising safety and efficacy in aggressive, radioiodine-resistant thyroid cancer, achieving a median PFS and OS of 29 and 32 months, respectively, with manageable adverse events. Confirmation of our findings is needed from prospective clinical trials comparing [177Lu]Lu-DOTAGA.FAPi dimer therapy to other treatments.
引用
- Ballal S, Yadav MP, Satapathy S, et al. Long-Term Outcomes in Radioiodine-Resistant Follicular Cell-Derived Thyroid Cancers Treated with [177Lu]Lu-DOTAGA.FAPi Dimer Therapy. Thyroid. 2025. PMID: 39869019. doi:10.1089/thy.2024.0229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。